The COVID-19 vaccine race isn’t over. As a result, there are various investment opportunities whether you are an aggressive investor or you have a low-risk appetite. What are the best COVID-19 vaccine stocks to buy right now for 2021?
A coronavirus vaccine probably won't be available for most people for months. However, investors might be wondering if they can invest some of their surplus cash into the companies that will likely roll out the COVID-19 vaccines — AstraZeneca, Moderna, and Pfizer — and earn a profit. Most of the vaccines were found to be over 90 percent effective in late-stage clinical trials.
In 2020, Moderna stock is already up over 470 percent as of midday trading on Dec. 30. Pfizer and AstraZeneca stocks have returned about -0.1 percent and 1.2 percent, respectively. Novavax stock has surged more than 2,800 percent this year.
There's hope that the COVID-19 vaccines will end the pandemic, which has killed millions of people globally. Currently, the U.S. has more than 19.5 million COVID-19 cases based on data compiled by Johns Hopkins University. At least 338,742 deaths in the U.S. have been linked to the coronavirus pandemic.
Pfizer stock is flat in 2020
Pfizer is developing its COVID-19 vaccine in partnership with BioNTech. The vaccine is based on the mRNA technology to prompt an immune response. The two companies have received emergency use authorization in the U.S., the U.K., and the European Union. Pfizer has received orders to supply nearly 550 million doses from several countries and regions including the European Union, the U.K, the U.S., and others. The number doesn’t include Canada, which ordered doses, but didn’t reveal how many.
Pfizer stock has fallen by 0.1 percent YTD. The stock is trading 13.9 percent below its 52-week high of $43.08 and 40.2 percent above its 52-week low of $26.45.
Moderna stock is up over 470 percent this year
Last week, the FDA approved Moderna’s experimental COVID-19 vaccine for emergency use. The company has received orders for over 470 million from the European Union, Canada, the U.S., Switzerland, and others. Like Pfizer, the number doesn’t include Singapore and Qatar, which ordered doses, but didn’t reveal how many.
Moderna stock has risen by 474 percent YTD. The stock is trading 37.2 percent below its 52-week high of $178.50 and 533.8 percent above its 52-week low of $17.68.
AstraZeneca stock is flat in 2020
AstraZeneca, which is based in the U.K., has been working with Oxford University to develop a COVID-19 vaccine. On Dec. 30, the experimental COVID-19 vaccine received emergency use authorization in the U.K. The country has ordered 100 million doses, while the U.S. has ordered 300 million doses. The U.S. government has also pledged up to $1.2 billion to help develop the vaccine.
AstraZeneca stock has risen by 0.7 percent YTD. The stock is trading 22.7 percent below its 52-week high of $64.94 and 38.9 percent above its 52-week low of $36.15.
Novavax and Johnson & Johnson are also developing their own COVID-19 vaccines. Their stocks were up 2,800 percent and 6.8 percent, respectively.